Updated financial calendar

OssDsign AB (publ) today announces that the financial calendar has been updated as the Annual Report for 2019 will be published on April 17th, 2020.

The dates for upcoming reports and the annual general meeting are set out below.

  • Annual Report 2019
    April 17th, 2020

     
  • Interim Report Q1 2020
    May 13th, 2020

     
  • Annual General Meeting 2020
    May 20th, 2020

     
  • Interim Report Q2 2020
    August 19th, 2020

     
  • Interim Report Q3 2020
    November 11th, 2020

     

For further information, please contact:
Anders Lundqvist, CEO, OssDsign AB

Tel: +46 73 206 98 08, email: al@ossdsign.com

 

Certified Adviser
The Company’s Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

 

About OssDsign
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.

Tags:

About Us

OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.

Subscribe

Documents & Links